Back To Search Instructions
11 protocols meet the specified criteria
Disease Site: Non-Hodgkin's Lymphoma
Protocol No.TitleStatus
0500000226Arizona Lymphoid Tissue and Blood Repository (ALTBR)Open
0900000967Lymphoma Outcomes and Epidemiological DatabaseOpen
1100000610A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications (10-CBA)Open
1100000642A Phase II Trial of PET-Directed Therapy for Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL) (S1001)Open
1410529443A Phase 2 Study of the Safety and Anti-tumor Activity of the Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients with refractory and/or Relapsed Richter's Transformation (RT)Open
1412602767A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Protective Efficacy and Safety of a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT) (0113-CL-1004)Open
1501635510Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients with Newly Diagnosed Diffuse Large B Cell LymphomaOpen
1502695269A Phase II, Open-Label Study Evaluating The Safety And Efficacy Of GDC-0199 (ABT-199) Plus Bendamustine Plus Rituximab (Br) In Comparison With Br Alone Or GDC-0199 Plus Rituximab (R) In Patients With Relapsed And Refractory Follicular Non-Hodgkin's LymphomaOpen
1505826794Pathogen Identification in Neutropenic Fever Oncology PatientsOpen
1506891752Intergroup Randomized Phase II Four Arm Study In Patients With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB → R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV→ R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB → LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV → LR) (E1411)Open
22245Investigating p21 activated kinases in lymphoma patientsOpen